Recently, the European Commission released the "Simplification Omnibus Package," proposing significant amendments to the existing Regulation (EC) No 1107/2009 on Plant Protection Products. Among these, the adjustments to the periodic review mechanism for active substances have garnered industry-wide attention. The draft explicitly proposes that the approval of active substances will, in principle, no longer have a fixed duration, and the periodic review mechanism will be weakened. This change marks a major shift in the EU's pesticide regulatory framework.

Background: Challenges and Bottlenecks of Periodic Review

Under the current regulation, active substances are typically approved for 10 to 15 years, requiring a renewal process before expiration. While this "fixed duration + mandatory review" model aims to ensure safety, it has also resulted in significant compliance costs and uncertainties. The European Commission noted in the draft's explanatory memorandum that issues such as limited evaluation capacity among member states and widespread delays in review processes have turned the periodic review system into a systemic regulatory bottleneck.

To address this issue, the EU proposes shifting from "periodic reassessment of all substances" to "targeted reviews based on new scientific evidence or identified risks" to improve regulatory efficiency.

Main Content: Core Changes in Active Substance Regulation

The key adjustments in the draft include the following:

1. Elimination of Fixed-Term Approvals

· Approvals for active substances will, in principle, no longer have a fixed expiration date.

· The periodic, automatically triggered review mechanism will be weakened, with time-bound management retained only in specific cases.

2. Introduction of a Temporary Review Mechanism

· Under Article 21, the European Commission can initiate a review at any time based on new scientific or technical evidence, without relying on fixed timeframes.

3. Special Management for Substances of High Concern

· Candidates for Substitution and substances approved under Article 4(7) exceptions will still be subject to time-bound management.

4. Transitional Arrangements

· Active substances approved before the new regulation takes effect will, in principle, be considered as having "indefinite approval".

· For substances with renewal applications already submitted, the renewal process will continue unaffected by the new regulation.

· For substances whose renewal applications are withdrawn during the review process, their approval will be formally revoked.

5. Priority Support for Biocontrol and Low-Risk Active Substances

· Plant Protection Products (PPPs) containing biocontrol or low-risk active substances will be prioritized for assessment and authorization.

· Pending the completion of active substance approval, relevant PPPs may be granted temporary authorization under specific conditions.

· Biocontrol PPPs are proposed to have a "single EU zone" authorization to accelerate market coverage.

Conclusion: Opportunities and Challenges Amid Regulatory Changes

The EU's adjustment to the periodic review mechanism for active substances reflects its effort to balance regulatory efficiency with scientific evidence. While the draft's final effective date remains uncertain, companies should begin preparations early to capitalize on compliance benefits from the policy changes while mitigating potential regulatory risks.

Going forward, as the draft progresses, related detailed rules and implementation plans are likely to be released. Companies must stay updated on developments from the European Commission to ensure compliance and business growth under the new regulatory framework.